Edgar Filing: BIOTECH GROWTH N V - Form 4

BIOTECH GROWTH N V

Form 4

November 16, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB APPROVAL OMB

3235-0287 Number:

January 31, Expires: 2005 Estimated average

0.5

burden hours per response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction

1(b).

Common

Stock

11/14/2017

(Print or Type Responses)

1. Name and Address of Reporting Person * BIOTECH GROWTH N V			2. Issuer Name and Ticklymbol	5. Relationship of Reporting Person(s) to Issuer			
(Last)	, ,	(Middle) 3.	Radius Health, Inc. [Factorial including the control of Earliest Transact Month/Day/Year) 1/14/2017	(Check Director Officer (give ti	X10% itleOther		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person		
CURACAO, P8 00000			_X_ Form filed by More than One Reporting Person			porting	
(City)	(State)	(Zip)	Table I - Non-Deriva	tive Securities Acq	uired, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		ate, if Transaction Dis Code (Instr	(A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

P

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

5,698,799

D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

50,000 A

Edgar Filing: BIOTECH GROWTH N V - Form 4

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exer	cisable and	7. Title an	nd 8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orNumber	Expiration D	ate	Amount o	of Derivative	e Deriv
Security	or Exercise		any	Code	of	(Month/Day	/Year)	Underlyin	ng Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivativ	ve .		Securities	(Instr. 5)	Bene
	Derivative				Securitie	s		(Instr. 3 an	nd 4)	Own
	Security				Acquired	l				Follo
	•				(A) or					Repo
					Disposed	l				Trans
					of (D)					(Instr
					(Instr. 3,					
					4, and 5)					
				C-1- V	(A) (D)	D-4-	Eiti	T:41- A	4	
				Code V	(A) (D)		Expiration		nount	
						Exercisable	Date	or		
									mber	
								of		
								Sha	ares	

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Othe		
BIOTECH GROWTH N V SNIPWEG 26 CURACAO, P8 00000		X				
BB BIOTECH AG SCHWERTSTRASSE 6 SCHAFFHAUSEN, V8 CH-8200		X				

Signatures

11/16/2017 /s/ Ivo Betschart Date **Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

Biotech Growth N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2